Comparing early and delayed therapy for high-risk patients with chronic lymphocytic leukemia.

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study collects data on healthcare utilization from newly diagnosed asymptomatic high-risk patients with chronic lymphocytic leukemia and small lymphocytic lymphoma across various Canadian centers. Patients will be monitored from registration until death, removal from the study, or completion of a 10-year follow-up. The study will gather information on study visits, radiographic assessments, laboratory tests, and treatment administration, supplemented by a self-administered resource utilization form to capture additional healthcare interactions. The aim is to analyze the economic implications of early versus delayed therapy in this patient population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patient must be eligible for the core CLC3/S1925 protocol.
* Patient consent must be appropriately obtained in accordance with applicable local and regulatory requirements. Each patient must sign a consent form prior to enrollment in the trial to document their willingness to participate.
* Patient is able (i.e. sufficiently fluent) and willing to complete the quality of life and/or health utility questionnaires in either English or French. The baseline assessment must be completed within required timelines, prior to enrollment. Inability (lack of comprehension in English or French, or other equivalent reason such as cognitive issues or lack of competency) to complete the questionnaires will not make the patient ineligible for the study. However, ability but unwillingness to complete the questionnaires will make the patient ineligible.
* Patients must be accessible for treatment and follow-up. Investigators must assure themselves the patients enrolled on this trial will be available for complete documentation of the treatment, adverse events, and follow-up.

Where it's running

• BCCA - Vancouver
  Vancouver, British Columbia, Canada Recruiting
• CancerCare Manitoba
  Winnipeg, Manitoba, Canada Recruiting
• Regional Health Authority B, Zone 2
  Saint John, New Brunswick, Canada Recruiting
• The Jewish General Hospital
  Montreal, Quebec, Canada Recruiting
• Lakeridge Health Oshawa
  Oshawa, Ontario, Canada Not yet recruiting
• Ottawa Hospital Research Institute
  Ottawa, Ontario, Canada Withdrawn

Study contacts

• Study coordinator: Annette Hay
• Email: ahay@ctg.queensu.ca
• Phone: 613-533-6430

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Venetoclax plus Zanubrutinib for CLL/SLL in frontline or previously treated patients

  This phase II trial tests if venetoclax plus zanubrutinib can safely and effectively treat adults with chronic lymphocytic leukemia or small lymphocytic lymphoma, including those who are newly diagnosed and those who have had prior therapy.

  Recruiting Phase 2 Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT07734038

• Tafasitamab plus Acalabrutinib and Venetoclax for newly treated CLL/SLL

  This phase II study tests a combination of tafasitamab, acalabrutinib, and venetoclax in adults who are newly diagnosed with chronic lymphocytic leukemia or small lymphocytic lymphoma to see if it is safe and effective.

  Recruiting at 2 sites Phase 2 City of Hope Medical Center · Duarte, California and 1 other locations · NCT07582159

• Nemtabrutinib and venetoclax in untreated CLL/SLL

  This phase 2 study tests whether combining nemtabrutinib with venetoclax can help people with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.

  Recruiting Phase 2 Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT07557056

• NX-5948 plus other medicines for B-cell cancers

  This trial tests NX-5948 in combination with venetoclax, with or without anti-CD20 antibodies, for adults with CLL/SLL or B-cell lymphoma that has returned or worsened or is newly diagnosed but needing treatment.

  Recruiting at 5 sites Phase 1/2 Nurix Therapeutics, Inc. · Aurora, Colorado and 8 other locations · NCT07520006

• NX-5948 vs Pirtobrutinib in R/R CLL/SLL

  This study tests NX-5948 against pirtobrutinib in people with relapsed or refractory CLL/SLL who have previously tried a covalent BTK inhibitor.

  Recruiting at 6 sites Phase 3 Nurix Therapeutics, Inc. · Macon, Georgia and 5 other locations · NCT07516093

• Rituximab and Tafasitamab with Allogeneic NK Cells for relapsed or refractory B-cell NHL

  This trial tests whether giving allogeneic NK cells with Rituximab, Tafasitamab, and IL-2 can help people with relapsed or refractory B-cell non-Hodgkin lymphoma who have tried at least two prior therapies.

  Recruiting Phase 1 Case Comprehensive Cancer Center · Cleveland, Ohio and 1 other locations · NCT07225439

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.